# **ORIGINAL ARTICLE**

# A toolbox approach for the rapid evaluation of multi-step enzymatic syntheses comprising a 'mix and match' *E. coli* expression system with microscale experimentation

# L. RIOS-SOLIS<sup>1</sup>, M. HALIM<sup>1</sup>, A. CÁZARES<sup>2</sup>, P. MORRIS<sup>1</sup>, J. M. WARD<sup>3</sup>, H. C. HAILES<sup>2</sup>, P. A. DALBY<sup>1</sup>, F. BAGANZ<sup>1</sup> & G. J. LYE<sup>1</sup>

<sup>1</sup>Department of Biochemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK, <sup>2</sup>Department of Chemistry, University College London, 20 Gordon Street, London, WC1H 0AJ, UK, <sup>3</sup>Institute of Structural and Molecular Biology, University College London, Gower Street, London, WC1E 6BT, UK

#### Abstract

This work describes an experimental 'toolbox' for the rapid evaluation and optimisation of multi-step enzymatic syntheses comprising a 'mix and match' E. coli-based expression system and automated microwell scale experimentation. The approach is illustrated with a de novo designed pathway for the synthesis of optically pure amino alcohols using the enzymes transketolase (TK) and transaminase (TAm) to catalyze asymmetric carbon-carbon bond formation and selective chiral amine group addition respectively. The E. coli expression system, based on two compatible plasmids, enables pairs of enzymes from previously engineered and cloned TK and TAm libraries to be evaluated for the sequential conversion of different initial substrates. This is complemented by the microwell experimentation which enables efficient investigation of different biocatalyst forms, use of different amine donors and substrate feeding strategies. Using this experimental 'toolbox', one-pot syntheses of the diastereoisomers (2S,3S)-2-aminopentane-1,3-diol (APD) and (2S,3R)-2-amino-1,3,4-butanetriol (ABT) were designed and performed, which gave final product yields of 90% mol/mol for APD and 87% mol/mol for ABT (relative to the initial TK substrates) within 25 hours. For the synthesis of APD, the E coli TK mutant D469E was paired with the TAm from Chromobacterium violaceum 2025 while for ABT synthesis the wild-type E. coli TK exhibited the highest specific activity and ee( enantiomeric excess) of >95%. For both reactions, whole-cell forms of the TK-TAm biocatalyst performed better than cell lysates while isopropylamine (IPA) was a preferable amine donor than methylbenzylamine (MBA) since side reactions with the initial TK substrates were avoided. The available libraries of TK and TAm enzymes and scalable nature of the microwell data suggest this 'toolbox' provides an efficient approach to early stage bioconversion process design in the chemical and pharmaceutical sectors.

Keywords: transketolase, transaminase, biocatalyst, multi-step enzymatic synthesis, chiral amino alcohols, de novo pathway

#### Introduction

Biological catalysts have repeatedly demonstrated their usefulness for chemical organic synthesis due to their moderate reaction conditions, reduced environmental impact and high regio- and stereo selectivity (Whitesides and Wong 2003). This has led to the successful investigation of multi-step, metabolically engineered pathways toward application as pharmaceutical production platforms (Wilkinson and Bachmann 2006). It is now possible to design *de novo* non-native pathways in heterologous hosts, to carry out specific non-natural bioconversions producing chiral compounds difficult to obtain by existing biosynthetic pathways or chemical synthesis (Lye et al. 2002, Burkart 2003, Roessner and Scott 2003, Prather and Martin 2008 Dalby et al. 2009). These studies have led to the rapid expansion of molecular pathway construction for the synthesis of a range of commodity fine chemicals and pharmaceutical intermediates (Wilkinson and Bachmann 2006).

The *de novo* design of synthetic pathways has recently been applied for the sequential two-step reaction of carbon–carbon bond formation using a

(Received 14 December 2010; revised 9 May 2011; accepted 28 July 2011)

ISSN 1024-2422 print/ISSN 1029-2446 online © 2011 Informa UK, Ltd. DOI: 10.3109/10242422.2011.609589

Correspondence: Professor Gary Lye, University College London, Biochemical Engineering, Torrington Place, London, WC1E 7JE United Kingdom. E-mail: g.lye@ucl.ac.uk



Scheme 1. Reaction scheme of the *de-novo* TK-TAm pathway for the synthesis of chiral amino-alcohol (2*S*,3*R*)-2-amino-1,3,4-butanetriol (ABT), from achiral substrates glycolaldehyde (GA) and hydroxypyruvate (HPA).

transketolase (TK) enzyme, followed by a transaminase (TAm) to create chiral amino alcohols from achiral substrates (Ingram et al. 2007). The amino alcohol moiety is a useful industrial synthon, necessary in the synthesis of several protease inhibitors (Kwon and Ko 2002), or broad spectrum antibiotics like chloramphenicol and thiamphenicol (Bhaskar et al. 2004, Boruwa et al. 2005). It also serves as chiral starting material for the synthesis of optically active molecules such as (S)-amphetamine (Rozwadowska 1993). The standard chemical synthesis route to produce optically pure amino alchohols is usually complex, requiring many steps in order to obtain the final product, resulting in low overall productivities (Hailes et al. 2009, Smithies et al. 2009).

Using erythrulose (ERY) and glycolaldehyde (GA) as achiral substrates, the one-pot synthesis of the single syn-diastereoisomer (2S,3R)-2-amino-1, 3,4-butanetriol (ABT) was previously demonstrated using *E. coli* whole cells expressing both wild type TK and a  $\beta$ -alanine-pyruvate TAm as shown in Scheme 1 (Ingram et al. 2007). ABT is an important building block which can be found in the core of the protease inhibitor drug Nelfinavir<sup>TM</sup> (Kaldor et al. 1997). The main limitation of this two step synthesis was the low activity of the  $\beta$ -alanine-pyruvate TAm causing a low overall yield of the reaction. Consequently we have constructed libraries of engineered TKs and novel TAms, which could be used to produce a range of the desired amino alcohols with

higher yields and stereoselectivities (Hibbert et al. 2007, Kaulmann et al. 2007, Hibbert et al. 2008, Smith et al. 2008). Subsequent work has shown that the synthesis of (2S,3S)-2-aminopentane-1,3-diol (APD) (Scheme 2) could be achieved in two separate TK and TAm bioconversions, where the enzymes selected were the E. coli TK mutant D469T and the Chromobacterium violaceum CV2025 TAm, reaching more than 90% mol/mol vield in each of the reaction steps (Smith et al. 2010). Compounds like APD containing the chiral 2-amino-1,3-diol moiety are generally an important class of pharmaceutical building blocks with their motif present in antibiotics, antiviral glycosidase inhibitors, and sphingo-lipids (Hailes et al. 2010). In this case, the required isolation of the TK product (3S)-1,3-dihydroxypentan-2-one (PKD) to perform the TAm bioconversion, led to a loss of more than 30% mol/mol of the intermediate. This could be potentially avoided by using a one-pot synthesis strategy, where the activities of the enzymes could be matched leading to higher yields of final product (Chen et al. 2006).

The aim of this work is to demonstrate a toolbox approach for the rapid evaluation of different variants of TK and TAm for the one-pot synthesis of a range of amino alcohols. The toolbox is based on an *E. coli* host where it is possible to systematically evaluate different pairs of the enzymes, screening them against different ketol donors, acceptors and amino donors. All the experiments were performed in



Scheme 2. Reaction scheme of the *de-novo* TK-TAm pathway for the synthesis of chiral amino-alcohol (2*S*,3*S*)-2-aminopentane-1,3-diol (APD) from achiral substrates propionaldehyde (PA) and hydroxypyruvate (HPA).

parallel at the microwell scale and could be readily automated and potentially scaled up following the procedure described in our previous works for fermentation and bioconversion (Micheletti and Lye 2006, Islam et al. 2008). The one-pot syntheses of ABT (Scheme 1) and (APD) (Scheme 2) were successfully demonstrated at 87 and 90 % mol/mol yields respectively, using the most appropriate forms of TK-TAm expressing biocatalysts.

# Materials and methods

# Materials

Molecular biology enzymes were obtained from New England Bio-laboratories (NEB, Hitchin, UK). Nutrient broth and nutrient agar were obtained from Fisher Scientific (Leicestershire, UK). Competent *E. coli* BL21-Gold (DE3) cells were obtained from Stratagene (Amsterdam, NL). All other reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless noted otherwise, and were of the highest purity available.

#### Synthesis of substrates and products

Hydroxypyruvate (HPA) was synthesized by reacting bromopyruvic acid with LiOH following a previously described method (Morris et al. 1996). PKD was synthesized in a 100 ml scale bioconversion with 300 mM HPA, 300 mM PA, 9 mM MgCl<sub>2</sub>, 2.4 mM thiamine pyrophosphate (TPP), at pH 7.0 and 30% v/v of D469E TK lysate (final TK concentration of 0.3 mg  $ml^{-1}$ ). The reaction was stirred for 10 h at room temperature in a sealed flask and the pH was maintained at 7.0 using a 718 STAT Titrino pH controller (Metrohm Ion Analysis, Switzerland). The solution was dried on silica and purified by column chromatography (ethyl acetate: hexane, 1:1) to yield PKD as a colorless oil that crystallized on standing. ABT and APD products were prepared in a multistep chemical synthesis described elsewhere (Ingram et al. 2007, Smith et al. 2010).

#### Plasmids

*Transketolase Plasmid and Mutagenesis.* Plasmid pQR412 contained the complete *E. coli* TK gene, *tktA*, with its native promoter and an N-terminal His6-tag. It was constructed using the expression vector pMMB67HE (8.8 kb), which has a RSF1010 origin of replication, the *tac* promoter, the Lac repressor and codes for resistance to ampicillin (Fürste et al. 1986). Even if the plasmid contained the inducible *tac* promoter, the expression of the

*E. coli tktA* was constitutive because of the presence of its native promoter (Ingram et al. 2007). Site directed mutagenesis of the TK gene was performed as described previously (Hibbert et al. 2007).

Transaminase Plasmid. Plasmid pQR801 contained the complete *Chromobacterium violaceum* 2025 TAm gene with an N-Terminal His6-tag (GenBank accession no. NP\_901695). Plasmid pQR801 was constructed using the expression vector pET29(a)+(5.3kb), which contains an inducible T7 promoter, the Lac repressor and codes for resistance to kanamycin (Kaulmann et al. 2007).

#### Biocatalysts

TK whole cell and lysate preparation. Competent E. coli BL21-Gold (DE3) cells were transformed with the plasmid pQR412 using the heat shock technique described by the supplier (Stratagene, Amsterdam, NL). An overnight culture of the transformed cells was obtained in a 100 ml shake flask (10 ml working volume) of LB-glycerol broth (10 g  $l^{-1}$  tryptone, 5 g  $l^{-1}$  yeast extract, 10 g  $l^{-1}$  NaCl and 10 g  $l^{-1}$ glycerol) containing 150  $\mu$ g ml<sup>-1</sup> ampicillin. Growth was performed at 37 °C with orbital shaking at 250 rpm using an SI 50 orbital shaker (Stuart Scientific, Redhill, UK). The total volume of this culture was used to inoculate a 1 litre shake flask (100 ml working volume) which was left to grow for 8 h. The cells were harvested and stored at -20°C following the removal of broth by centrifugation. When a TK lysate was needed, the cells were resuspended in 50 mM TRIS buffer, at pH 7.5 and sonicated with a Soniprep 150 sonicator (MSE, Sanyo, Japan). The lysate suspension was centrifuged at 5000 rpm in Falcon tubes for 5 min and then stored at -20°C and used within 1 month. Prior to the initiation of a bioconversion, the frozen lysates (300  $\mu$ l) were thawed in a water bath at 30°C for typically 10 min and then immediately incubated with cofactors.

TAm whole cell and TK-TAm biocatalyst preparation. Transformation of *E. coli* BL21-Gold (DE3) cells with the plasmid pQR801 and inoculum preparation were performed in the same way as described in Section 2.4.1, except that 150  $\mu$ g ml<sup>-1</sup> of kanamycin were used for the single transformed cells and 50  $\mu$ g ml<sup>-1</sup> of both kanamycin and ampicillin were used for the double transformed strain. To construct the double transformed biocatalyst, 50  $\mu$ l of competent *E. coli* BL21-Gold (DE3) cells were double transformed with a 1  $\mu$ l solution of plasmids pQR412 and pQR801 (50  $\mu$ g ml<sup>-1</sup> for each plasmid) using the heat shock technique described by the supplier (Stratagene, Amsterdam, NL). For whole cell bioconversions, fresh cells were always used and they were produced as follows: after inoculation of a 1 litre shake flask (100 ml working volume), when the  $OD_{600}$  reached a value of 1.5-2, isopropylthiogalactopyranoside (IPTG) was added to a final concentration of 0.2 mM. After 4 hr induction, the cells were harvested and following the removal of broth by centrifugation, they were resuspended in 50 mM HEPES buffer, at pH 7.5 and used for whole cell bioconversions. When lysates were needed, after the resuspension, the cells were sonicated and stored using the same procedure described in the previous Section.

#### Bioconversion kinetics

Microscale experimental platform. All bioconversions were performed in a glass 96-well, flat-bottomed microtiter plate with individual wells having a diameter of 7.6 mm and height of 12 mm (Radleys Discovery Technologies, Essex, UK). The microplate was covered with a thermo plastic elastomer cap designed to work with automated equipment (Micronic, Lelystad, Netherlands). All the bioconversions were performed using 300 µl total volume at 30°C, at pH 7.5 unless noted otherwise, and shaking was provided at 400 rpm with a Thermomixer Comfort shaker (shaking diameter of 3 mm, Eppendorf, Cambridge, UK). TK single step reactions were performed in 50 mM TRIS buffer and the concentration of cofactors MgCl<sub>2</sub> and thiamine pyrophosphate (TTP) were 9 mM and 2.4 mM respectively for all reactions. TAm single step reactions and all the two step syntheses were carried out in 50 mM HEPES buffer, and the concentration of TAm cofactor pyridoxal-5-phosphate (PLP) was 0.2 mM in all cases. (S)- $(\alpha)$ -Methyl benzylamine (MBA) or isopropylamine (IPA) were added as amino donors as indicated in the results section at final concentrations of 10 mM and 100 mM respectively unless noted otherwise. A final concentration of 0.3 mg ml<sup>-1</sup> of TK or TAm was used in all the single enzyme reactions. For whole cell bioconversion, 1.5 and 2.3  $g_{DCW}$  l<sup>-1</sup> (where DCW is dry cell weight)were used for the single TAm assays and for the one-pot syntheses respectively. The whole cell suspension or lysate with the cofactor solutions were always added first in the well and left to incubate for 20 min at 30°C, prior to initiation of the reaction by addition of the substrate solutions. Preliminary experiments showed that the initial cofactor incubation helped to ensure that all expressed TK or TAm was in the active holoform. This practice also enabled more consistent measurement of specific activity results, by avoiding initial non linear reaction kinetics believed to be caused in some cases by the binding of the enzyme and cofactors. Aliquots of 20 µl were taken at various time intervals and quenched with 380 µl of a 0.1% v/v trifluoroacetic acid (TFA) solution. They were then centrifuged for 5 min at 5000 rpm and transferred into an HPLC vial for further analysis. All experiments were performed in triplicate. The specific activities were determined as the amount of PKD, ERY, acetophenone (AP), APD and ABT formed per unit of time normalized by the amount of enzyme used in the reaction. The specific activity was based on the measured mass of TAm or TK present in each bioconversion. For whole cell experiments, it was calculated based on 50% of the dry cell weight of the cells being protein (Watson 1972), combined with the measured result of the percentage of TK and TAm by SDS-PAGE analysis.

#### Analytical methods

Biomass concentration was measured as optical density at 600 nm (OD<sub>600</sub>) using a spectrophotometer (Thermo Spectronic, Cambridge, UK) and converted to dry cell weight (DCW) using a calibration curve where 1  $OD_{600} = 0.5 \text{ g}_{DCW} \text{ } l^{-1}$ . Protein concentrations of the lysates were obtained using the Bradford assay and SDS-PAGE as described previously (Kaulmann et al. 2007). A Dionex HPLC system (Camberley, UK) with a Bio-Rad Aminex HPX-87H reverse phase column (300  $\times$  7.8 mm, Bio-Rad Labs., Richmond, CA, USA), controlled by Chromeleon client 6.60 software was used for the separation and analysis of PKD, ERY and HPA. The system comprised a GP50 gradient pump, a FAMOS autosampler, an LC30 chromatography column oven and an AD20 UV/Vis absorbance detector. The HPLC method used has been described previously (Chen et al. 2008). To quantify MBA, AP, APD and ABT, an integrated Dionex ultimate 3000 HPLC system (Camberley, UK) with an ACE 5 C18 reverse phase column (150mm  $\times$  4.6 mm, 5 µm particle Advance Chromatography Technologies, size; Aberdeen, UK) controlled by Chromeleon client 6.60 software was employed. The HPLC method has been reported elsewhere (Kaulmann et al. 2007). To analyse ABT and APD, the samples were derivatized by addition of an excess of 6-aminoquinolyl-Nhydroxysuccinimidyl carbamate. The derivatizing reagent was made in house following the protocol of Cohen and Michaud (1992), and the HPLC method used has been described previously (Ingram et al. 2007). Previously characterized by MS and NMR, the enantiomeric excess (ee) of the ketodiols was determined by derivatization via dibenzoylation for satisfactory peak resolution by chiral HPLC. This was performed on a Varian Prostar instrument equipped with a Chiracel AD chiral column (Daicel; Chiral Technologies Europe, France, 25 cm  $\times$  0.46 cm) and

a mobile phase of n-hexane/2-propanol solvent mixture (90:10 v/v) was used. The method has been described in more detail elsewhere (Cázares et al. 2010). The ee of ABT and APD was determined by first derivatizing the amino alcohol to the respective benzoate form. The assay was performed against the four diastereomer samples of the benzoate synthesized as described elsewhere (Smith et al. 2010) using chiral HPLC: Chiracel-OD column (Daicel); mobile phase, isopropanol/hexane (5:95); flow rate, 0.8 mL/min, detection, UV 210 nm. Figure 1 shows examples of HPLC profiles for the chiral separation and ee determination of (3S)-1,3-dihydroxypentan-2 -one (S-PKD) and (3R)-1,3-dihydroxypentan-2-one (R-PKD), as well as the HPLC profiles for the detection and quantification (non chiral) of APD, HPA, ERY, PKD, AP and MBA.

# **Results and discussion**

#### **Biocatalyst Production**

In order to separately regulate expression of the TK and TAm enzymes in E. coli, a dual plasmid system was selected to facilitate the "mix and match" approach first proposed by Hussain and Ward (2003). This is based on two plasmids with different origins of replication and antibiotic resistance genes that would enable the rapid evaluation of different variants of TK and TAm. To establish the metabolic burden of the two plasmids on the host cells, five different whole cell biocatalysts were initially generated and evaluated in shake flask fermentations. Growth kinetics were obtained with cultures of E. coli BL21-Gold (DE3) containing either no plasmid, the single TK or TAm gene expressing plasmids, or both the TK and TAm plasmids, in each case either induced or non induced (Figure 2).

Single transformed strains with plasmid pQR412 (TK) or pQR801 (TAm) reached biomass concentrations of 2.1 and 1.8  $g_{DCW}$  l<sup>-1</sup> respectively. These were 12.5% and 25% less than for the non transformed strain respectively. The double transformed and induced strain obtained a final biomass concentration of 1.2  $g_{DCW}$  l<sup>-1</sup>, representing nearly a 50% decrease compared to the non transformed strain. This decrease in growth, however, was compensated by the increase in enzyme synthesis which was expected due to the metabolic burden caused by the maintenance and expression of two plasmids.

In terms of enzyme expression levels, TK and TAm (induced with IPTG) in the single transformed cells were found to represent 20% and 40% w/w of the total protein respectively. For the double transformed strain, the TK concentration diminished compared to the single TK plasmid strain, and after



Figure 2. Shake flask fermentation kinetics for *E. coli* BL21-Gold (DE3) grown in LB-glycerol medium at 37°C with ( $\mathbf{v}$ ) untransformed cells, and cells transformed with ( $\Delta$ ) pQR412 (TK), ( $\mathbf{\bullet}$ ) pQR801 (CV2025 TAm), ( $\bigcirc$ ) double transformed uninduced strain with pQR801 and pQR412, ( $\square$ ) double transformed strain induced with 0.2 mM IPTG after 6 h of cell growth. Error bars represent one standard deviation about the mean (n = 3).

inducing at a biomass concentration of 1  $g_{DCW}$  l<sup>-1</sup> for 4 hs, the final enzyme expression of TK and TAm represented 8% and 36% w/w of the total protein. Because of the significantly lower activity of the TAm compared to the TK (Chen et al. 2006, Ingram et al. 2007), this method of induced expression of TK and TAm was considered acceptable and was used to prepare all the biocatalysts for the later two-step bioconversions. Related work in our group is focusing on fine control of the expression levels of the two enzymes, so that the optimum proportions can be obtained for specific bioconversions.

#### Considerations for two-step TK-TAm syntheses

The use of multi-step enzymatic syntheses necessarily requires some compromises to be made regarding the optimum reaction conditions for each enzyme. This is particularly acute with isolated enzymes but can be alleviated, to some extent, by the use of whole cell biocatalysts. Optimum conditions reported for TK-catalyzed ketodiol syntheses were pH 7.0 using TRIS buffer at 25°C (Chen et al. 2006, Hibbert et al. 2007, Cázares et al. 2010). The best conditions for the CV2025 TAm to catalyze syntheses of various amino alcohols were at pH 7.5 using HEPES buffer at 37°C (Kaulmann et al. 2007, Smithies et al. 2009). In order to evaluate the process compromises to be made, the synthesis of 10 mM ABT using MBA as amino donor was used as a reference



R-PKD S-PKD 20 30 40 Retention time (min) APD HPA ERY HPA PKD AP 0 0 2 6 8 16 10 12 14 4 Retention time (min)

Figure 1. HPLC profiles from different reaction mixtures obtained as described in Section 2.5 for (a) the chiral separation and ee determination of (3S)-1,3-dihydroxypentan-2-one (S-PKD) and (3R)-1,3-dihydroxypentan-2-one (R-PKD), and for the detection and quantification (non chiral) of (b) APD, (c) HPA and ERY, (d) HPA and PKD, (e) AP and (f) MBA. HPLC conditions and details about the samples preparation are described in Section 2.6.

reaction (Scheme 1). Control TK reactions in the presence of the working concentration of the TAm cofactor PLP demonstrated that this did not have any effect on the TK reaction. The same finding was

obtained for the effect of TPP and Mg<sup>2+</sup> on the TAm bioconversion. Reactions of TK carried at a pH of 7.5 showed a decrease of TK activity of 30% (data not shown), nevertheless this pH was selected for subsequent studies considering the generally higher activity of TK compared to TAm as described above.

In terms of reaction temperature, a control reaction using a lysate of untransformed E. coli BL21-Gold (DE3) showed that at 37°C up to 50% of the HPA substrate was consumed by side reactions after 2 h, while at 30°C, less than 5% of HPA was consumed over the same time (data not shown). Consequently the TK-TAm reactions were performed at 30°C to avoid HPA metabolism. With regards to buffer selection, control experiments using TRIS and phosphate buffer inhibited the CV2025 TAm. We have previously shown that HEPES buffer catalyses several side reactions between HPA and aldehydes at 37°C (Smith et al. 2006b), nevertheless at 30°C, control experiments showed that less than 5% of HPA was lost by the biomimetic activity of 50 mM HEPES after 2 h. Based on all these considerations, the reaction conditions selected for the in vitro evaluation of the different TK-TAm variants were 30 °C and pH 7.5 in 50 mM HEPES buffer.

#### Bioconversions with TK

Both the TK and TAm bioconversions were initially studied individually under conditions suitable for later two-step reactions established in the previous section. Information on specific activities, *ee* and final yields gathered from those experiments will then enable us to successfully "mix and match" the best pair of enzymes to synthesize specific amino alcohols. Initial TK kinetics experiments showed that the activities and final yields obtained with *E. coli* TK lysates and whole cells were similar (data not shown), therefore data reported here for TK bioconversions were performed only with lysates containing the different TK variants (Table 1).

From TK mutant libraries developed previously (Hibbert et al. 2008, Smith et al. 2008), the TK variants D469E, D469T and the wild type TK were selected as candidates due to their catalytic potential for the synthesis of ERY and/or PKD. Using HPA, the TK reactions were irreversible due to the release of  $CO_2$  as a side product, and yields of more than 90% mol/mol were obtained using concentrations up to 300 mM of HPA and the aldehyde GA or PA (data not shown). In contrast, TAm reaction high yields were limited to around 10 mM using MBA as amino donor, hence initial TK bioconversions studies were performed at this lower concentration.

Figure 3 shows the kinetics of ketodiol production for different combinations of TKs and aldehyde acceptors. The quantified activities, yields and measured *ee* values are summarised in Table I. The wild type TK was selected for ERY synthesis because it



Figure 3. Bioconversion kinetics showing ketodiol synthesis using different TK lysates and aldehyde acceptors: (•) ERY with wild type TK, (•) ERY with D469T TK, (•) ERY with D469E TK, ( $\triangle$ ) PKD with D469T TK, ( $\square$ ) PKD with D469E TK, ( $\bigcirc$ ) PKD with wild type TK. Reaction conditions: 10 mM HPA and GA, 2.4 mM TTP, 9 mM Mg<sup>2+</sup>, 0.3 mg ml<sup>-1</sup> TK, pH 7.5 in 50 mM TRIS, 30°C. Error bars represent one standard deviation about the mean (n = 3).

presented the highest activity and *ee* of 6.6  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup> and >95% respectively. Gyamerah and Willetts (1997) obtained an activity of 13.2  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup> for the same HPA and GA reaction using wild type *E. coli* TK. This is in agreement with the work described here considering the differences in concentration of substrates used. For the synthesis of PKD, the highest activity was 1.98  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup> using the TK mutant D469T, while no activity after 70 min of reaction was detected using the wild type enzyme. The *ee* of PKD obtained with TK D469E was >90%, compared to a 64% *ee* of D469T. Due to the importance of the *ee* in the synthesis of optically pure amino alcohols, the TK mutant D469E

Table I. Measured TK specific activities, product yields and *ee* for the lysate catalyzed bioconversions shown in Figure 3.

TK variant	$\begin{array}{c} Specific \ activity^{a,c}\\ Aldehyde \ (\mu mol \ min^{-1} \ mg^{-1}) \ \ ee \ (\%) \end{array}$			Final yield <sup>b</sup> (% mol/mol)
Wild type	GA	$6.62 \pm 0.13$	>95	100
Wild type	PA	< 0.1	nd <sup>d</sup>	<1
D469T	GA	$5.13 \pm 0.43$	85	95
D469T	PA	$1.98\pm0.27$	64	98
D469E	GA	$4.96 \pm 0.39$	nd	100
D469E	PA	$1.49\pm0.26$	>90	90

<sup>a</sup>The specific activity is based on the measured mass of TK in each bioconversion.

<sup>b</sup>Yield was determined at t = 70 min.

<sup>c</sup>The error of the specific activity represents one standard deviation about the mean (n = 3).

<sup>d</sup>Nd = not determined.

was selected, even though it had a 25% lower activity than D469T. The D469E mutation is in the pyrimidine binding domain of TK, and is assumed to enable activity towards PA because it replaces the original interaction of Asp with the C-2 hydroxyl group of GA, by creating a specific interaction between the Glu and the methyl group of the new substrate (Hibbert et al. 2008, Cázares et al. 2010).

#### Bioconversions with TAm

Single step TAm bioconversions focused on the CV2025 TAm as it had already been shown to be the best candidate for amino alcohol synthesis among several other transaminases cloned by us in previous work (Kaulmann et al. 2007). The CV2025 TAm showed a 4 fold increase in yield and a 40 fold improvement in specific activity (Figure IV and Table II) compared to initial work with a  $\beta$ -alanine-pyruvate transaminase (Ingram et al. 2007). The cV2025 TAm has not previously been reported, so it is investigated here where a whole cell TAm biocatalyst is compared with a lysate form for syntheses of a number of ketodiols.

Figure 4 shows product formation kinetics using either MBA or IPA as amino donors and PKD as amino acceptor. Due to the volatility of IPA, an excess concentration of 100 mM IPA was initially used instead of 10 mM MBA to compensate for any loss due to evaporation. The results of activities and final yields of both amino alcohols are summarised in Table II. The final yield of ABT of 92 and 86% mol/mol using whole cell and lysates respectively improved our previously reported values of 14-22% mol/mol (Kaulman et al. 2007). The quantitative conversion of the reaction observed in Figure 4 and Table II is in agreement with the equilibrium constants obtained for a similar transamination of pyruvate with MBA using the  $\omega$ -transaminase from Bacillus thuringiensis JS64, showing that the forward reaction was thermodynamically more favorable than the reverse reaction (Shin and Kim 1998). Smith et al. (2010) obtained a 93% mol/mol yield for the synthesis of APD with the CV2025 TAm using an excess of PKD (molar ratio of 1.5 PKD/ IPA). In this work, the use of whole cells enabled us to reach an almost complete conversion of the substrates with a final yield of 96% mol/mol without having to use an excess of the chiral ketodiol. Nevertheless we observed that working with higher concentrations severely inhibited the bioconversion; in this case the use of *in situ* product removal by ion exchange resins or coupled reactions could be a



Figure 4. Bioconversion kinetics showing APD synthesis using CV2015 TAm in either lysate or whole cell form with different amino donors: ( $\bullet$ ) whole cell with MBA, ( $\blacktriangle$ ) whole cell with IPA, ( $\bigcirc$ ) lysate with MBA, ( $\triangle$ ) lysate with IPA. Reaction conditions : 10 mM MBA or 100 mM IPA, 10 mM PKD, 0.2 mM PLP, 0.3 mg ml<sup>-1</sup> TAm, pH 7.5 in 50 mM HEPES, 30°C. Error bars represent one standard deviation about the mean (n = 3).

possible solution as has been shown by others (Truppo et al. 2010).

Similar yields were obtained using ERY or PKD as substrates, but the specific activities using ERY were between 17% and 42% higher than those of PKD. For synthesis of both amino alcohol products, the whole cell biocatalysts performed better than the lysates demonstrating the beneficial effect of using TAm *in vivo* for these bioconversions. This phenomenon has also been reported in the literature, where higher yields using whole cell TAm biocatalysts have

Table II. Measured specific activities and product yields for the TAm catalyzed conversion of PKD and ERY.

Biocatalyst form	Amino donor	Amino acceptor	Specific activity <sup>a,c</sup> (µmol min <sup>-1</sup> mg <sup>-1</sup> )	Final yield <sup>b</sup> (% mol/mol)
Whole cell	MBA	PKD	$0.074\pm0.006$	95
Lysate	MBA	PKD	$0.034\pm0.003$	83
Whole cell	IPA	PKD	$0.029 \pm 0.0035$	96
Lysate	IPA	PKD	$0.015 \pm 0.003$	75
Whole cell	MBA	ERY	$0.096 \pm 0.005$	92
Lysate	MBA	ERY	$0.045\pm0.003$	86
Whole cell	IPA	ERY	$0.035\pm0.05$	91
Lysate	IPA	ERY	$0.026\pm0.04$	71

<sup>a</sup>The specific activity was based on the measured mass of TAm present in each bioconversion. For whole cell experiments, it was calculated based on 50% of the dry cell weight of the cells being protein (Watson 1972), and SDS-PAGE analysis that showed that 40% of the protein was TAm.

<sup>b</sup>Yield was determined at t = 30 h.

<sup>c</sup>The error of the specific activity represents one standard deviation about the mean (n = 3).

been attributed to better stability of the enzyme inside the cell (Shin and Kim 1997), to metabolism consumption of inhibitory compounds (Shin and Kim 1999), or to the effect of the cell membrane in partitioning inhibitory components between the inside and outside of the cell (Yun et al. 2004). In this work, the inhibitory product acetophenone (AP) was not further metabolised by the whole cells and MBA and AP where found to be more inhibitory than IPA and acetone (Figure 5). In contrast, when using TAm lysates, lower yields were obtained using IPA (75% and 71% mol/mol for APD and ABT respectively) compared to MBA (83% and 86% mol/ mol respectively). Addition of more enzyme and PLP after the initial reaction had stopped, partially restored the biocatalytic activity, suggesting that the improved vield using whole cells could be attributed to an increase in stability of the enzyme. Figure 5 shows the kinetics of TAm production of APD using initial equimolar concentration of substrates of 50 mM PKD with IPA or MBA as amino donors. After 40 h, the final yields were 52 and 23% using IPA and MBA respectively, underlying the strong inhibition caused by MBA. This inhibitory effect of MBA has also been reported in the literature with transaminases from Klebsiella pneumonia and Vibrio fluvialis (Shin and Kim 1997, Yun et al. 2004).

Based on the results in Table II, the whole cell TAm biocatalyst was selected for further study because of its superior performance compared to the lysate. IPA appears preferable as amine donor



Figure 5. Bioconversion kinetics showing APD synthesis using CV2015 TAm in whole cell form with different amine donors: (•) 50 mM PKD and MBA and ( $\Delta$ ) 50 mM PKD and IPA. Reaction conditions: 0.2 mM PLP, 0.3 mg ml<sup>-1</sup> TAm, pH 7.5 in 50 mM HEPES, 30°C. Error bars represent one standard deviation about the mean (n = 3).

because of its advantages in terms of economy, downstream processing and reduced inhibition compared to MBA. However, both amine donors were evaluated for one-pot synthesis reactions in the next section.

#### One-Pot synthesis of amino alchohols

In order to achieve the one-pot synthesis of amino alcohols, two whole cell biocatalysts were constructed both with plasmid pQR801 expressing the CV2025 TAm, and with either pQR412 expressing the TK mutant D469E or the wild type variant for APD and ABT syntheses respectively. The first onepot synthesis of APD using MBA as amino donor gave a poor yield (15% mol/mol) of amino alcohol after 20 h but another product was detected by HPLC analysis. This compound was identified as serine, which was possibly produced by the transamination of HPA. To overcome this problem, MBA was subsequently added in fed batch mode after the TK reaction was complete (Figure 6). The volume of the solution of MBA added was equal to the volume of the reaction mixture, hence the original concentration of the reactants was diluted 2-fold after MBA addition. The first step comprising the TK reaction reached completion after 4 h with a specific activity of 2.68  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup>. The second step TAm reaction, reaction had a specific activity of 0.067  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup> and reached a maximum APD yield of 90% mol/mol after 21 h of reaction



Figure 6. Typical bioconversion kinetics for the one-pot, whole cell TK-TAm catalytic synthesis of APD with addition of amine donor (MBA) after 4 h : ( $\mathbf{v}$ ) PKD, ( $\mathbf{\bullet}$ ) HPA, ( $\Delta$ ) APD, ( $\diamond$ ) MBA and ( $\bigcirc$ ) AP. Reaction conditions (TK step): 20 mM HPA and PA, 0.4 mM PLP, 2.4 mM TTP, 9 mM Mg<sup>2+</sup>, 0.095 mg ml<sup>-1</sup> TK, 0.43 mg ml<sup>-1</sup> TAm, pH 7.5 in 50 mM HEPES, 30°C. TAm step was initiated by adding MBA solution which resulted in a 2 fold dilution of reactants.

with MBA. This measured activity is in agreement with the one found for the single TAm reaction (Table II).

When using IPA as amine donor at the compromise temperature of 30°C, the TAm did not show any noticeable activity towards HPA, GA or PA over 5 h (data not shown). This was not the case at 37°C, where activity towards TK substrates was detected in that period of time. This suggested that it was possible to perform the bioconversion of APD using IPA in a true one-pot synthesis at 30°C as shown in Figure 7, were the TK reaction was completed after 5 h, leading to a 90% mol/mol yield of APD after 25 h. The specific activities of TK and TAm in the one-pot synthesis were 1.46 and 0.022  $\mu$ mol min<sup>-1</sup> mg<sup>-1</sup> respectively, which were also in agreement with the corresponding TK and TAm specific activities for the single bioconversions (Table I and II). Similar results were obtained for the one-pot synthesis of ABT using IPA as amine donor, reaching a final yield of 87% mol/mol after 25 h (Figure 8). The TK reaction for the ABT synthesis was completed in 1.5 h instead of the 5 h required for the APD synthesis. This was in agreement with the higher activity of the wild type TK enzyme towards ERY synthesis in comparison to the activity of the D469E variant towards PKD synthesis (Table I).

Taking all these results together demonstrated the utility of the 'mix and match' microscale experimental system for rapidly evaluating pairs of enzymes and the interaction of reaction conditions.



Figure 7. Typical bioconversion kinetics for the one-pot, whole cell TK-TAm catalytic synthesis of APD using IPA as amine donor: ( $\checkmark$ ) PKD, ( $\bigcirc$ ) HPA, and ( $\triangle$ ) APD. Reaction conditions: 10 mM HPA and PA, 100 mM IPA, 0.2 mM PLP, 2.4 mM TTP, 9 mM Mg<sup>2+</sup>, 0.095 mg ml<sup>-1</sup> TK , 0.42 mg ml<sup>-1</sup> TAm, pH 7.5 in 50 mM HEPES, 30°C.

IPA was also seen to be a preferable amine donor compared to MBA, and the whole cell biocatalyst performed better than the lysate. The 87% mol/mol yield for ABT synthesis represented an improvement of 4-fold in yield in a quarter of the reaction time compared to our previous work (Ingram et al. 2007). The 90% mol/mol yield for APD represented a 2-fold improvement yield in a third of the reaction time compared to our previous two-step synthesis (Smith et al. 2010).

# Conclusions

The microscale 'toolbox' described in this work has been shown to enable the efficient evaluation and "mix and match" of pairs of TK and TAm enzymes for the one-pot synthesis of optically pure amino alcohols. In particular the CV2025 TAm was found to display better catalytic activity when used in vivo leading to the selection of whole cell biocatalysts for the synthesis of the single diastereoisomers of both ABT and APD. IPA was identified as a preferable amine donor compared to MBA for the one-pot syntheses because side reactions with the initial TK substrates (catalysed by TAm) were negligible and higher yields could be obtained at higher concentrations. Our current work is seeking to increase the size of the available TK and TAm libraries and to expand the available microscale methods for evaluation of subsequent product recovery and purification operations.



Figure 8. Typical bioconversion kinetics for the one-pot, whole cell TK-TAm catalytic synthesis of ABT using IPA as amine donor: ( $\checkmark$ ) ABT, ( $\bullet$ ) HPA, and ( $\bigcirc$ ) ERY. Reaction conditions: 10 mM HPA and GA, 100 mM IPA, 0.2 mM PLP, 2.4 mM TTP, 9 mM Mg<sup>2+</sup>, 0.095 mg ml<sup>-1</sup> TK, 0.42 mg ml<sup>-1</sup> TAm, pH 7.5 in 50 mM HEPES, 30°C.

# Acknowledgements

The Mexican National Council for Science and Technology (CONACYT), The Mexican Ministry of Public Education (SEP), The Ministry of Higher Education of Malaysia (MOHE) and The Royal Thai Government are acknowledged for the support to the authors of this work. The UK Engineering and Physical Sciences Research Council (EPSRC) is thanked for the support of the multidisciplinary Biocatalysis Integrated with Chemistry and Engineering (BiCE) programme (GR/S62505/01) at University College London (London, UK). The help from the thirteen industrial partners supporting the BiCE programme is also acknowledged.

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. The studentships was supported by the Mexican National Council for Science and Technology (CONACYT), the Mexican Ministry of Public Education (SEP), the Ministry of Higher Education of Malaysia (MOHE) and he Royal Thai Government.Moreover, financial support was provided bythirteen industrial partners supporting the BiCE programme.

## References

- Bhaskar G, Satish KV, Venkateswara RB, 2004. A short stereoselective synthesis of (–)chloramphenicol and (+)-thiamphenicol. Tetra Asym 15:1279–1283.
- Boruwa J, Borah JC, Gogoi S, Barua NC. 2005. A short asymmetric total synthesis of chloramphenicol using a selectively protected 1,2-diol. Tetra Lett 46:1743–1746.
- Burkart MD. 2003. Metabolic engineering-a genetic toolbox for small molecule organic synthesis. Org Biomol Chem; 1: 1–4.
- Cázares A, Galman JL, Crago LG, Smith MEB, Strafford J, Rios-Solis L, et al.2010. Non-a-hydroxylated aldehydes with evolved transketolase enzymes. Org Biomol Chem 8:1301–1309.
- Chen BH, Hibbert EG, Dalby PA. 2008. A new approach to bioconversion reaction kinetic parameter identification. AIChE J 58:2155–2163.
- Chen BH, Sayar A, Kaulmann U, Dalby PA, Ward JM, Woodley JM. 2006. Reaction modelling and simulation to assess the integrated use of transketolase and  $\omega$ -transaminase for the synthesis of an aminotriol. Biocat Biotrans 24:449–457.
- Cohen SA, Michaud DP.1993. Synthesis of a fluorescent derivatizing reagent, 6-aminoquinolyl-*N*-hydroxysuccinimidyl carbamate, and its application for the analysis of hydrolysate amino acids via high-performance liquid chromatography. Anal Biochem 211: 279–287.
- Dalby PA, Baganz F, Lye GJ, Ward JM. 2009. Protein and pathway engineering in biocatalysis. Chim Ogg 27:18–22.
- Fürste JP, Pansegrau W, Frank R, Blöcker H, Scholz P, Bagdasarian M, Lanka E. 1986. Molecular cloning of the plasmid RP4 primase region in a multi-host-range tacP expression vector. Gene 48:119–131.

- Gyamerah M, Willetts AJ. 1997. Kinetics of overexpressed *transketolase* from *Escherichia coli* JM 107/pQR 700. Enzyme Microbial Technol 20:127–134.
- Hailes HC, Dalby PA, Lye GJ, Ward, JM. 2009. Biocatalytic approaches to ketodiols and aminodiols. Chim Oggi 27: 28–31.
- Hibbert EG, Senussi T, Costelloe SJ, Lei W, Smith MEB, Ward JM, et al. 2007. Directed evolution of transketolase activity on non-phosphorylated substrates. J Biotechnol 131: 425–432.
- Hibbert EG, Senussi T, Smith MEB, Costelloe SJ, Ward JM, Hailes HC, Dalby PA. 2008. Directed evolution of transketolase substrate specificity towards an aliphatic aldehyde. J Biotechnol 134:240–245.
- Hussain HA, Ward JM. (2003) Enhanced Heterologous Expression of Two Streptomyces griseolus Cytochrome P450s and Streptomyces coelicolor Ferredoxin Reductase as Potentially Efficient Hydroxylation Catalysts. Appl Environ Microbiol 69: 373–382.
- Ingram CU, Bommer M, Smith MEB, Dalby PA, Ward J. M., Hailes HC, Lye GJ. 2007. One-pot synthesis of amino-alcohols using a *de-novo* transketolase and β-alanine:pyruvate transaminase pathway in *Escherichiacoli*. Biotechnol Bioeng 96: 559–569.
- Islam RS, Tisi D, Levy MS, Lye GJ. (2008) Scale-up of *E. coli* growth and recombinant protein expression conditions from microwell to laboratory and pilot scale based on matched kLa. Biothecnol Bioeng 99:1128–1139.
- Kaldor WK, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, et al. 1997. Viracept (Nefinavir Mesylate, AG1343): A potent, orally available inhibitor of HIV-1 protease. J Med Chem 40: 3979–3985.
- Kaulmann U, Smithies K, Smith MEB, Hailes HC, Ward JM. 2007. Substrate spectrum of ω-transaminase from *Chromobacterium violaceum* DSM30191 and its potential for biocatalysis. Enz Microb Tech 41:628–637.
- Kwon SJ, Ko SY. 2002. Synthesis of statine employing a general syn-amino alcohol building block. Tetra Lett 43:639–641.
- Lye GJ, Dalby PA, Woodley J M. 2002. Better biocatalytic processes faster: new tools for the implementation of biocatalysis in organic synthesis. Org Proc Res Dev 6:434–440.
- Micheletti M, Lye GJ. 2006. Microscale bioprocess optimization. Curr Opin Biotechnol 17:611–618.
- Morris KG, Smith MEB, Turner NJ, Lilly MD, Mitra RK, Woodley JM. 1996. Transketolase from *Escherichia coli*: A practical procedure for using the biocatalyst for asymmetric carboncarbon bond synthesis. Tetra Asym 7:2185–2188.
- Prather KL, Martin CH. 2008. *De novo* biosynthetic pathways: rational design of microbial chemical factories Curr Opin Biotechnol 19:468–474.
- Roessner CA, Scott AI .2003. Achieving natural product synthesis and diversity via catalytic networking *ex vivo*. Chem Biol 3: 325–330.
- Rozwadowska MD. 1993. An efficient synthesis of (S)-(+)amphetamine. Tetra Asymm 4:1619–162.
- Shin JS, Kim BG. 1997. Kinetic resolution of  $\alpha$ -methylbenzylamine with w-transaminase screened from soil microorganisms: application of a biphasic system to overcome product inhibition. Biotechnol Bioeng 55:348–358.
- Shin JS, Kim BG. 1998. Kinetic modeling of  $\omega$ -transamination for enzymatic kinetic resolution of  $\alpha$ -methylbenzylamine. Biotechnol Bioeng 60:534–40.
- Shin JS, Kim BG. 1999. Asymmetric synthesis of chiral amines with ω-transaminase. Biotechnol Bioeng 65:206–211.
- Smith MEB, Chen BH, Hibbert EG, Kaulmann, U, Smithies K, Galman JL, et al. .2010. A multidisciplinary approach toward the rapid and preparative-scale biocatalytic synthesis of chiral

RIGHTSLINKA)

amino alcohols: a concise transketolase-/w-transaminase-mediated synthesis of (2S,3S)-2-aminopentane-1,3-diol. Org Proc Res Dev 14:99–107.

- Smith MEB, Hibbert EG, Jones AB, Dalby PA, Hailes HC. 2008. Enhancing and reversing the stereoselectivity of *Escherichia coli* transketolase via single-point mutations. Adv Syn Cat 350: 2631–2638.
- Smith MEB, Kaulmann U, Ward JM, Hailes HC. 2006a. A colorimetric assay for screening transketolase activity. Bioorg Med Chem 14:7062 –7065.
- Smith MEB, Smithies K, Senussi T, Dalby PA, Hailes HC. 2006b. The first mimetic of the transketolase reaction. Eur J Org Chem 5:1121–1123.
- Smithies K, Smith MEB, Kaulmann U, Galman JL, Ward JM, Hailes HC. 2009. Stereoselectivity of an ω-transaminase-

mediated amination of 1,3-dihydroxy-1-phenylpropane-2-one. Tetrahedron: Asymm 20:570–574.

- Truppo MD, Rozzell JD, Turner NJ. 2010. Efficient production of enantiomerically pure chiral amines at concentrations of 50g/L using transaminases. Org Process Res Dev 14: 234–237.
- Watson JD. 1972 .Molecular Biology of the Gene. 2nd ed., Philadelphia, PA: Saunders.
- Yun H, Cho BK, Kim BG. 2004. Kinetic resolution of (*R*,*S*)secbutylamine using omega-transaminase from *Vibrio fluvialis* JS17 under reduced pressure. Biotechnol Bioeng 87: 772–777.
- Whitesides GN, Wong CH. 2003. Enzymes as catalysts in synthetic organic chemistry. Angew Chem Int Ed 24:617–638.
- Wilkinson B, Bachmann BO. 2006. Biocatalysis in pharmaceutical preparation and alteration. Curr Opin Chem Biol 10: 169–176.